Literature DB >> 19018532

Peroxisome proliferator-activated receptor gamma overexpression and knockdown: impact on human B cell lymphoma proliferation and survival.

Tatiana M Garcia-Bates1, Scott A Peslak, Carolyn J Baglole, Sanjay B Maggirwar, Steven H Bernstein, Richard P Phipps.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a multifunctional transcription factor that regulates adipogenesis, immunity and inflammation. Our laboratory previously demonstrated that PPARgamma ligands induce apoptosis in malignant B cells. While malignant B lineage cells such as B cell lymphoma express PPARgamma, its physiological function remains unknown. Herein, we demonstrate that silencing PPARgamma expression by RNAi in human Burkitt's type B lymphoma cells increased basal and mitogen-induced proliferation and survival, which was accompanied by enhanced NF-kappaB activity and increased expression of Bcl-2. These cells also had increased survival upon exposure to PPARgamma ligands and exhibited a less differentiated phenotype. In contrast, PPARgamma overexpression in B lymphoma cells inhibited cell growth and decreased their proliferative response to mitogenic stimuli. These cells were also more sensitive to PPARgamma-ligand induced growth arrest and displayed a more differentiated phenotype. Collectively, these findings support a regulatory role for PPARgamma in the proliferation, survival and differentiation of malignant B cells. These findings further suggest the potential of PPARgamma as a therapeutic target for B cell malignancy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018532      PMCID: PMC3003604          DOI: 10.1007/s00262-008-0625-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  58 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Burkitt's lymphoma: a single disease with multiple variants. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues.

Authors:  E S Jaffe; J Diebold; N L Harris; H K Muller-Hermelink; G Flandrin; J W Vardiman
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

3.  PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties.

Authors:  M Amine Bouhlel; Bruno Derudas; Elena Rigamonti; Rébecca Dièvart; John Brozek; Stéphan Haulon; Christophe Zawadzki; Brigitte Jude; Gérard Torpier; Nikolaus Marx; Bart Staels; Giulia Chinetti-Gbaguidi
Journal:  Cell Metab       Date:  2007-08       Impact factor: 27.287

4.  Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.

Authors:  Marina Konopleva; Twee Tsao; Peter Ruvolo; Irina Stiouf; Zeev Estrov; Clinton E Leysath; Shourong Zhao; David Harris; Shirong Chang; C Ellen Jackson; Mark Munsell; Nanjoo Suh; Gordon Gribble; Tadashi Honda; W Stratford May; Michael B Sporn; Michael Andreeff
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

5.  The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms.

Authors:  Denise M Ray; Filiz Akbiyik; Richard P Phipps
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

6.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

7.  Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis.

Authors:  K Setoguchi; Y Misaki; Y Terauchi; T Yamauchi; K Kawahata; T Kadowaki; K Yamamoto
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

8.  Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene.

Authors:  B A Beamer; C Negri; C J Yen; O Gavrilova; J M Rumberger; M J Durcan; D P Yarnall; A L Hawkins; C A Griffin; D K Burns; J Roth; M Reitman; A R Shuldiner
Journal:  Biochem Biophys Res Commun       Date:  1997-04-28       Impact factor: 3.575

Review 9.  Emerging roles of PPARs in inflammation and immunity.

Authors:  Raymond A Daynes; Dallas C Jones
Journal:  Nat Rev Immunol       Date:  2002-10       Impact factor: 53.106

10.  Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.

Authors:  Denise Kelly; Jamie I Campbell; Timothy P King; George Grant; Emmelie A Jansson; Alistair G P Coutts; Sven Pettersson; Shaun Conway
Journal:  Nat Immunol       Date:  2003-12-21       Impact factor: 25.606

View more
  10 in total

Review 1.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

2.  A prospective analysis of circulating saturated and monounsaturated fatty acids and risk of non-Hodgkin lymphoma.

Authors:  Yu-Han Chiu; Kimberly A Bertrand; Shumin Zhang; Francine Laden; Mara M Epstein; Bernard A Rosner; Stephanie Chiuve; Hannia Campos; Edward L Giovannucci; Jorge E Chavarro; Brenda M Birmann
Journal:  Int J Cancer       Date:  2018-08-10       Impact factor: 7.396

3.  A role for Egfl7 during endothelial organization in the embryoid body model system.

Authors:  Anna Durrans; Heidi Stuhlmann
Journal:  J Angiogenes Res       Date:  2010-02-19

4.  Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

Authors:  P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps
Journal:  PPAR Res       Date:  2010-02-28       Impact factor: 4.964

Review 5.  Mechanisms underlying the association between obesity and Hodgkin lymphoma.

Authors:  Andreia Matos; Joana Marinho-Dias; Sofia Ramalheira; Maria José Oliveira; Manuel Bicho; Ricardo Ribeiro
Journal:  Tumour Biol       Date:  2016-07-27

6.  Peroxisome proliferator-activated receptor γ B cell-specific-deficient mice have an impaired antibody response.

Authors:  Sesquile Ramon; Simona Bancos; Thomas H Thatcher; Thomas I Murant; Safiehkhatoon Moshkani; Julie M Sahler; Andrea Bottaro; Patricia J Sime; Richard P Phipps
Journal:  J Immunol       Date:  2012-10-05       Impact factor: 5.422

7.  Peroxisome proliferator-activated receptor gamma ligands enhance human B cell antibody production and differentiation.

Authors:  Tatiana M Garcia-Bates; Carolyn J Baglole; Matthew P Bernard; Thomas I Murant; Patricia J Simpson-Haidaris; Richard P Phipps
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

8.  The influence of Cox-2 and bioactive lipids on hematological cancers.

Authors:  Sesquile Ramon; Collynn F Woeller; Richard P Phipps
Journal:  Curr Angiogenes       Date:  2013-09-01

9.  Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone.

Authors:  Mario Nava-Villalba; Rosa E Nuñez-Anita; Alexander Bontempo; Carmen Aceves
Journal:  Mol Cancer       Date:  2015-09-17       Impact factor: 27.401

Review 10.  PPARγ and the Innate Immune System Mediate the Resolution of Inflammation.

Authors:  Amanda Croasdell; Parker F Duffney; Nina Kim; Shannon H Lacy; Patricia J Sime; Richard P Phipps
Journal:  PPAR Res       Date:  2015-12-02       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.